Literature DB >> 7621435

Increased mRNA expression of the receptor-like protein tyrosine phosphatase alpha in late stage colon carcinomas.

K Tabiti1, D R Smith, H S Goh, C J Pallen.   

Abstract

The protein tyrosine phosphatase alpha (PTP alpha) mRNA level in paired samples of late stage (Dukes' D) colorectal tumors and adjacent normal colon mucosa was quantified by RNase protection assays. After normalization against 18S RNA or beta-actin mRNA level, a 2-10-fold increase in PTP alpha mRNA was detected in 10 of 14 tumors (approximately 70%) compared to mucosa. In situ hybridization of digoxigenin-labelled antisense PTP alpha RNA to tumor and mucosa sections produced a signal only in neoplastic cells of the tumor sample, consistent with the high increase in PTP alpha mRNA detected by RNase protection assays of some of the tumors. This is the first report suggesting an association of a protein tyrosine phosphatase with colorectal carcinoma. PTP alpha is a receptor-like PTP thought to be involved in regulating cell proliferation. Its oncogenic properties when overexpressed in cultured fibroblasts suggest that PTP alpha overexpression could contribute to the tumorigenic process in colon carcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7621435     DOI: 10.1016/0304-3835(95)03816-f

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

Review 1.  Role of protein tyrosine phosphatases in cancer.

Authors:  Tasneem Motiwala; Samson T Jacob
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

2.  Receptor protein-tyrosine phosphatase α regulates focal adhesion kinase phosphorylation and ErbB2 oncoprotein-mediated mammary epithelial cell motility.

Authors:  Benoit Boivin; Fauzia Chaudhary; Bryan C Dickinson; Aftabul Haque; Stephanie C Pero; Christopher J Chang; Nicholas K Tonks
Journal:  J Biol Chem       Date:  2013-11-11       Impact factor: 5.157

Review 3.  Inside the human cancer tyrosine phosphatome.

Authors:  Sofi G Julien; Nadia Dubé; Serge Hardy; Michel L Tremblay
Journal:  Nat Rev Cancer       Date:  2011-01       Impact factor: 60.716

4.  Receptor-like protein tyrosine phosphatase alpha homodimerizes on the cell surface.

Authors:  G Jiang; J den Hertog; T Hunter
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

5.  Activation of Src and transformation by an RPTPα splice mutant found in human tumours.

Authors:  Jian Huang; Ling Yao; Rongting Xu; Huacheng Wu; Min Wang; Brian S White; David Shalloway; Xinmin Zheng
Journal:  EMBO J       Date:  2011-07-01       Impact factor: 11.598

6.  Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer.

Authors:  Ping-Hui Sun; Lin Ye; Malcolm D Mason; Wen G Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-04       Impact factor: 4.553

7.  Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi.

Authors:  Xinmin Zheng; Ross J Resnick; David Shalloway
Journal:  Int J Cancer       Date:  2008-05-01       Impact factor: 7.396

8.  The interaction of protein-tyrosine phosphatase α (PTPα) and RACK1 protein enables insulin-like growth factor 1 (IGF-1)-stimulated Abl-dependent and -independent tyrosine phosphorylation of PTPα.

Authors:  Ranvikram S Khanna; Hoa T Le; Jing Wang; Thomas C H Fung; Catherine J Pallen
Journal:  J Biol Chem       Date:  2015-02-18       Impact factor: 5.157

9.  Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.

Authors:  Zhidong Gu; Xuqian Fang; Chang Li; Changqiang Chen; Guangshu Liang; Xinming Zheng; Qishi Fan
Journal:  Int J Oncol       Date:  2017-06-23       Impact factor: 5.650

10.  Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability.

Authors:  Sebastian Korff; Stefan M Woerner; Yan P Yuan; Peer Bork; Magnus von Knebel Doeberitz; Johannes Gebert
Journal:  BMC Cancer       Date:  2008-11-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.